Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lower Doses of CPX-351 in Older Patients With Relapsed/Refractory AML and MDS
NCT04668885Phase 2Active, not recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 5 years. Started Jan 2021; status: active, not recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04668885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668885.